Pharmaceutical firm Merck & Co. Inc. (NYSE: MRK) reported internet revenue for the second quarter of 2024, on an adjusted foundation, in comparison with a loss final yr. Each gross sales and earnings exceeded the market’s expectations.
Second-quarter worldwide gross sales elevated 7% year-over-year to $16.11 billion, primarily reflecting continued progress within the gross sales of vaccines and oncology/cardiovascular merchandise. Wall Road was in search of slower progress.
The corporate reported a internet revenue of $5.46 billion or $2.14 per share for the June quarter, in comparison with a lack of $5.98 billion or $2.35 per share within the prior-year interval. On an adjusted foundation, internet earnings was $2.28 per share, in comparison with a lack of $2.06 per share within the second quarter of 2023. The underside line topped expectations.
“I’m happy with our devoted groups all over the world which are working tirelessly to advance our deep pipeline as we proceed delivering innovation that solves unmet medical wants,” mentioned Merck’s CEO Robert Davis.
